Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy

doi:10.4239/wjd.v13.i5.387

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7071)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

372

WORD

103

HTML

3575

Figures (1-4)

628

Tables (1-2)

350

Sum=5028

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

222

Download

461

Sum=683

Publishing Process of This Article

Item

Count

Browse

426

Download

934

Sum=1360

May 15, 2022 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Frontier

World J Diabetes. May 15, 2022; 13(5): 387-407
Published online May 15, 2022. doi: 10.4239/wjd.v13.i5.387

Full Size Figure Download Figure

Figure 1 Molecular mechanisms of diabetic cardiomyopathy. Hyperglycemia and insulin resistance increase reactive oxygen species formation, oxidative stress, advanced glycation end-products formation, and the recruitment of various inflammatory pathways leading to cardiac dysfunction and heart failure. ROS: Reactive oxygen species.

Citation: El-Azab MF, Wakiel AE, Nafea YK, Youssef ME. Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy. World J Diabetes 2022; 13(5): 387-407
URL: https://www.wjgnet.com/1948-9358/full/v13/i5/387.htm
DOI: https://dx.doi.org/10.4239/wjd.v13.i5.387